P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
| Autor: | Lordick, F., Orra, E. Buxó, Cervantes, A., Dayyani, F., Rocha-Lima, C., Greil, R., Laarhoven, H. van, Lorenzen, S., Kischel, R., Shitara, K., Chao, J. |
|---|---|
| Zdroj: | In Annals of Oncology July 2020 31 Supplement 3:S114-S114 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|